The device was created in collaboration with SlitLED and featuring AutoAquire, RemotePilot, and Multi-Slit views.

At Glaucoma 360 2025, Danica Marrelli, OD, FAAO, dove into the data on visual field testing for patients with glaucoma.

Attention to patients' near visual needs is warranted when choosing medications.

Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.

Now, the VTO platform features 3 different offerings, 2 which are new and 1 which has been updated, according to the company.

The CREST Registry study reported on the safety and effectiveness outcomes of microinvasive cyclodialysis clef formation with the CycloPen system, followed by scleral reinforcement with AlloFlo Bio-Tissue implantation, according to Iantrek.

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the possibility of a sale.

Misconceptions often lead to missed diagnoses.

Catch up on what happened in optometry during the week of February 3-February 7.

Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The company sits at spot 43 for “its outstanding performance in areas including unit growth, financial strength and stability, and brand power."

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Both patient and provider benefit from reduced contact lens wear cycles.

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded.

All QLS-111 concentrations and dose regimens in both Osprey and Apteryx trials “demonstrated excellent safety and tolerability,” according to the company.

The goal of the agreement is to advance Eleva’s current programs into mid- and late-stage clinical development.

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.